Johnson & Johnson was swept into a mounting legal crisis centered on allegations that its talc-based products caused cancer.

In April 2021, Swiss pharmaceutical giant Roche celebrated the approval of its novel anti-influenza drug, Baloxavir Marboxil, in China.

In July 2024, Roche filed a lawsuit in a California district court that thrust Stanford University professors Maximilian Diehn and Ash Alizadeh into the center of a major controversy.

The patent dispute between Swiss pharmaceutical giant Roche and American biotech heavyweight Biogen over Tocilizumab has emerged as a focal point in the global competition surrounding biosimilars.

In March 2025, the global pharmaceutical sector witnessed a surge of innovation where technology deeply integrates with clinical needs, spanning key areas.

Hansoh Pharma entered into a strategic collaboration with Merck & Co. worth over $2 billion, granting Merck the exclusive global license for its investigational GLP-1 receptor agonist, HS-10535.

Johnson & Johnson announced its acquisition of Intra-Cellular Therapies, a biopharmaceutical company focused on central nervous system (CNS) disorders.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered significant attention for their dual effects in glucose control and weight reduction.

The siRNA therapeutics market is expected to grow substantially from $12.7 billion in 2022 to $39.2 billion by 2029.

In an era characterized by information overload, effectively managing and utilizing vast amounts of biomedical data has become another pressing issue.

In recent years, a molecular target known as Claudin18.2 has emerged as a prominent target in the treatment of gastric cancer, pancreatic cancer, and various other solid tumors.

the Antibody-Drug Conjugates (ADCs) market has entered a new phase of rapid growth since 2019, maintaining an annual growth rate exceeding 30%.